Ambrx Biopharma Inc.

NYSE: AMAM · Real-Time Price · USD
28.00
0.02 (0.07%)
At close: Mar 06, 2024, 10:00 PM

Ambrx Biopharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2022 FY 2021
Period Ending Dec 31, 2022 Dec 31, 2021
Revenue
7.4M 7.46M
Cost of Revenue
n/a n/a
Gross Profit
7.4M 7.46M
Operating Income
-57.08M -64.42M
Interest Income
369K n/a
Pretax Income
-76.06M -68.29M
Net Income
-78M -68.29M
Selling & General & Admin
23.05M 17.07M
Research & Development
53.31M 54.81M
Other Expenses
-2.22M n/a
Operating Expenses
74.14M 71.88M
Interest Expense
968K n/a
Selling & Marketing Expenses
2.73M n/a
Cost & Expenses
-83.83M 71.88M
Income Tax Expense
1.94M 1K
Shares Outstanding (Basic)
38.61M 20.45M
Shares Outstanding (Diluted)
38.61M 20.45M
EPS (Basic)
-2.02 -3.34
EPS (Diluted)
-2.02 -3.34
EBITDA
-55.79M -62.27M
EBIT
-64.46M -64.42M
Depreciation & Amortization
1.29M 2.15M